Zhendong Pharmaceutical Secures China Promotion Rights to Ferring’s Sodium Picosulfate
Shanxi Zhendong Pharmaceutical Co., Ltd. (SHE: 300158) has entered a strategic partnership with Ferring Pharmaceuticals...
GenAssist Therapeutic Partners with Indian DART Foundation on Duchenne Muscular Dystrophy Base Editing
Suzhou GenAssist Therapeutic Co., Ltd. has signed a Memorandum of Understanding (MoU) with India’s Dystrophy...
Foresee Pharmaceuticals Licenses MMP-12 Inhibitor Portfolio to Primevera for $584.5 Million
Foresee Pharmaceuticals has entered an exclusive global licensing agreement with Primevera Therapeutics, a German biotech...
Formosa Pharmaceuticals Licenses APP13007 Eye Drops to Samil Pharma for South Korea Market
Formosa Pharmaceuticals, Inc. (TPE: 6838) has entered an exclusive licensing agreement with Samil Pharmaceuticals Co.,...
Nanjing Hanxin Licenses AC02 ACTH Analogue to Amphastar for $151 Million US/Canada Deal
Nanjing Hanxin Pharmaceutical Technology Co., Ltd. has entered a licensing agreement with Amphastar Pharmaceuticals, Inc....
Chia Tai Fenghai Licenses FHND5032 miR-124 Inducer to Formation Bio for $500 Million
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CTFH) has entered a strategic licensing agreement with...
Henlius Biotech Secures Global Rights to U-mab’s IL-1RAP Antibody in Licensing Deal
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced a licensing agreement with U-mab Biopharma, acquiring exclusive...
Zhongsheng Pharma Licenses RAY1225 GLP-1/GIP Dual Agonist to Qilu Pharma for $144 Million
Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has entered a strategic licensing agreement with Qilu...
Kintor Pharma Signs Exclusive China Distribution Deal for Anti-Hair Loss Foam with Dekai Med
Kintor Pharmaceutical Limited (HKG: 9939) has entered an exclusive marketing service agreement with Beijing Dekai...
Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage
Huadong Medicine Co., Ltd (SHE: 000963) announced a key milestone in its strategic collaboration with...
Bao Pharma Partners with Shanghai RAAS to Develop Subcutaneous Blood Products Using Hyaluronidase Technology
Shanghai Bao Pharmaceuticals Co., Ltd. (HKG: 2659) has entered a strategic partnership with Shanghai RAAS...
Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market
Delonix Bioworks announced that DX-104, its Group B meningococcal (MenB) vaccine candidate, has received clinical...
Peijia Medical Files CE Mark for GeminiOne TEER System in European Mitral Regurgitation Market
Peijia Medical Ltd (HKG: 9996) announced it has submitted CE mark registration under the European...
Novartis Breaks Ground on $23 Billion US Biomedical Research Center in San Diego
Novartis AG (NYSE: NVS) held a groundbreaking ceremony for a state-of-the-art global biomedical research center...
Sino Biopharm Completes Phase III Enrollment for LM-302 ADC in Gastric Cancer
Sino Biopharmaceutical Ltd (HKG: 1177) announced completion of patient enrollment for the registrational Phase III...
Gilead’s Kite Pharma Secures FDA Label Expansion for Yescarta in Primary CNS Lymphoma
Kite Pharma, a Gilead Sciences (NASDAQ: GILD) subsidiary, announced that the U.S. Food and Drug...
Jenscare Scientific’s LuX-Valve Plus Wins FDA Nod for US Pivotal Trial in Tricuspid Regurgitation
Jenscare Scientific Co., Ltd. (HKG: 9877) announced that the U.S. Food and Drug Administration (FDA)...
Hengrui Pharma’s HRS-4642 Wins Breakthrough Therapy Designation for KRAS G12D Pancreatic Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS-4642, its KRAS G12D-targeting...
Pfizer’s Hympavzi Wins FDA Priority Review for Pediatric Hemophilia Expansion
Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has accepted...
Zhongsheng Pharma Reports Positive Phase III Data for Onradivir Pediatric and Adolescent Influenza Trials
Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced positive top-line results from two Phase III...